By Matteo Castia

Pharmaceutical group AstraZeneca PLC said Friday that its Farxiga drug to treat chronic kidney disease has been granted the breakthrough therapy designation by the U.S. Food and Drugs Administration.

Farxiga demonstrated the effect of reducing the risk of kidney failure and cardiovascular or renal death in patients with chronic kidney disease in a phase 3 clinical trial.

The breakthrough therapy designation is a status the FDA grants to accelerate the development and regulatory review of potential new medicines that are intended to treat a serious condition and address a significant unmet medical need.

Write to Matteo Castia at matteo.castia@dowjones.com

(END) Dow Jones Newswires

October 02, 2020 02:26 ET (06:26 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Astrazeneca
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Astrazeneca